Description

Hims & Hers May Have Just Rewritten Its Entire Business Model!

Hims & Hers Health did not report a surprise quarter, unveil a major product launch, or raise guidance when the stock rallied after Robert F. Kennedy Jr.’s announcement on peptides. That is what made the move notable. The reaction was not really about immediate earnings power. It was about a change in how investors view the company’s future economics, especially after months of debate around GLP-1s, compounding, branded distribution, and whether the business could preserve its profitability profile as regulation evolved. The policy shift reopened the possibility that certain peptide categories could move back toward a clearer compounding pathway after being constrained under prior rules. That matters because the company has already spent years building a direct-to-consumer care platform centered on personalization, supply control, and vertical integration.